Lithium (carbonate / citrate) Withdrawal & Tapering Guide
lithium
In short
Lithium (carbonate / citrate) (lithium) is a Mood Stabilizer with a half-life of 18-24 hours (longer in older adults and renal impairment). Very slow taper recommended (months, not weeks). Withdrawal symptoms, when they occur, usually begin Days to weeks after stopping (mania risk peaks 2-12 weeks) and settle within Variable — many never re-establish mood stability after stopping long-term lithium. It is also sold as Eskalith, Lithobid, Camcolit, Priadel.
- Class
- Mood Stabilizer
- Half-life
- 18-24 hours (longer in older adults and renal impairment)
- Common doses
- 300mg capsules/tablets, 450mg ER, oral solution 300mg/5mL
- Withdrawal onset
- Days to weeks after stopping (mania risk peaks 2-12 weeks)
- Typical resolution
- Variable — many never re-establish mood stability after stopping long-term lithium
Educational reference only. Dose changes are decided with the prescriber who knows your history.
Overview
Lithium is the gold-standard mood stabilizer for bipolar disorder, with the strongest evidence for reducing suicide risk of any psychiatric medication. It has a narrow therapeutic window — therapeutic and toxic levels are close, requiring blood-level monitoring.
300mg capsules/tablets, 450mg ER, oral solution 300mg/5mL
Capsules: 150mg, 300mg, 600mg; Tablets ER: 300mg, 450mg; Oral solution: 300mg/5mL (citrate)
Category D
Mechanism of Action
Mechanism not fully understood. Inhibits inositol monophosphatase and glycogen synthase kinase-3 (GSK-3); modulates second-messenger systems. Effects on circadian rhythm and neuroprotection are likely contributors.
Taper Notes
Very slow taper recommended (months, not weeks). Abrupt discontinuation carries documented mania and suicide risk. Monitor mood and suicidality closely.
Hyperbolic Tapering Guidance
Of all psychiatric medications, lithium has the most substantial post-discontinuation risk profile (mania, suicide, refractoriness). Plan very slow tapers with mood monitoring.
Summary written by TaperCommunity, informed by the Maudsley Deprescribing Guidelines (Horowitz & Taylor) and related literature — see Sources & References below. Not affiliated with or endorsed by the Maudsley.
Withdrawal Timeline
Days to weeks after stopping (mania risk peaks 2-12 weeks)
4-12 weeks
Variable — many never re-establish mood stability after stopping long-term lithium
Lithium-discontinuation refractoriness: some patients lose response to lithium if restarted after stopping
Common Withdrawal Symptoms
Interactions & Safety
Drug Interactions
- NSAIDs, ACE inhibitors, ARBs, thiazide diuretics — increase lithium levels (toxicity risk)
- Caffeine, theophylline — decrease lithium levels
- Antipsychotics (especially haloperidol) — risk of neurotoxicity at therapeutic levels
Contraindications
- Severe renal impairment
- Severe cardiovascular disease
- Pregnancy first trimester (Ebstein anomaly risk; benefit may still outweigh)
Toxicity
NARROW THERAPEUTIC INDEX. Toxicity at levels >1.5 mEq/L: tremor, ataxia, confusion, seizures, renal failure. Chronic use: hypothyroidism (~10-20%), nephrogenic diabetes insipidus, weight gain, fine tremor, cognitive blunting, long-term renal decline. Monitor TSH, creatinine, lithium level.
Pharmacokinetics
ADME Profile
Renal — virtually entirely. Sodium/water status directly affects lithium levels.
Need a clinician who understands tapering?
Browse our map of deprescribing-informed providers worldwide.
Other Drug Profiles
Frequently asked questions about Lithium (carbonate / citrate)
What are the withdrawal symptoms of Lithium (carbonate / citrate) (lithium)?
Common withdrawal symptoms of Lithium (carbonate / citrate) (lithium) include: rebound mania (significant — within weeks of stopping), anxiety, sleep disturbance, rapid mood swings, increased suicide risk especially with abrupt discontinuation. Symptom severity varies by individual, dose, and duration of use.
How should I taper off Lithium (carbonate / citrate) (lithium)?
Very slow taper recommended (months, not weeks). Abrupt discontinuation carries documented mania and suicide risk. Monitor mood and suicidality closely. Of all psychiatric medications, lithium has the most substantial post-discontinuation risk profile (mania, suicide, refractoriness). Plan very slow tapers with mood monitoring.
How long does Lithium (carbonate / citrate) withdrawal last?
Lithium (carbonate / citrate) withdrawal typically begins Days to weeks after stopping (mania risk peaks 2-12 weeks), peaks around 4-12 weeks, and resolves within Variable — many never re-establish mood stability after stopping long-term lithium. Lithium-discontinuation refractoriness: some patients lose response to lithium if restarted after stopping
Can I stop Lithium (carbonate / citrate) cold turkey?
Stopping Lithium (carbonate / citrate) abruptly is not recommended. Its half-life is 18-24 hours (longer in older adults and renal impairment), and the receptor adaptations built up during treatment do not reverse at that speed, so a sudden stop tends to produce the sharpest withdrawal. Prescribing guidance favours gradual, proportional reductions agreed with your prescriber.
How long does Lithium (carbonate / citrate) stay in your system?
Lithium (carbonate / citrate) (lithium) has a half-life of 18-24 hours (longer in older adults and renal impairment). A drug is mostly cleared after about five half-lives, so Lithium (carbonate / citrate) is largely out of the body roughly 4 to 5 days after the last dose, longer in older adults or with liver or kidney impairment. Withdrawal symptoms often begin before the drug has fully cleared and continue after it has, because the adaptations the brain made during treatment reverse more slowly than the drug leaves the blood.
Sources & References
Lithium (carbonate / citrate) (lithium) information on this page is sourced from peer-reviewed research, regulatory bodies, clinical guidelines, and patient-advocacy organizations.
Encyclopedic & chemical databases
Neutral, high-authority entity references.
Regulatory sources
Official prescribing information and safety notices.
Peer-reviewed research
Primary literature cited in this taper guide.
- Goodwin GM, Haddad PM, Ferrier IN, et al. 2016 — Discontinuation of mood stabilizers: practical considerations and review (Journal of Psychopharmacology)
- Geddes JR, Burgess S, Hawton K, et al. 2004 — Discontinuation of lithium augmentation in elderly patients (American Journal of Psychiatry)
- Horowitz MA, Taylor D 2019 — Tapering of SSRI treatment to mitigate withdrawal symptoms (hyperbolic taper) (The Lancet Psychiatry)
Clinical guidelines
Evidence-based deprescribing and prescribing standards.
Deprescribing-specific resources
Clinician-facing references on tapering protocols.
- International Society for Bipolar Disorders (ISBD) — Specialty society guidance for bipolar maintenance pharmacotherapy
- Deprescribing.org — Clinician-facing deprescribing algorithms
Patient-advocacy & lived-experience
Long-running communities documenting withdrawal experience.
- Surviving Antidepressants — mood stabilizer tapering forum — Community archive of mood-stabilizer discontinuation experiences
- Mad in America — mood stabilizer coverage — Independent journalism on lithium, lamotrigine, and valproate
- Inner Compass Initiative — Withdrawal Project — Peer-led psychiatric drug withdrawal resources
- RxISK — adverse drug reaction reporting — Independent database of mood-stabilizer adverse-effect reports
TaperCommunity does not provide medical advice. Always consult a qualified prescriber before adjusting psychiatric medication.